Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given Milestone Pharmaceuticals its first FDA approval in its 22-year history. The ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
The US Food and Drug Administration has approved etripamil nasal spray (Cardamyst) for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), drugmaker Milestone ...
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results